CytoSorbents™

HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE

NASDAQ: CTSO

Cowen 41st Annual Healthcare Conference

March 3, 2021
Safe Harbor Statement

This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "intend," "target," "will," "is likely," "would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements are found at various places throughout this presentation and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts. Unless otherwise indicated, the terms “CytoSorbents,” “Company,” “we,” “us” and “our” refer to CytoSorbents Corporation. Any or all of the forward-looking statements included in this presentation are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies’ products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable presentation. You are referred to a discussion of important risk factors detailed in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 5, 2020 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.
CytoSorbents

Leading the Prevention or Treatment of Life-Threatening Inflammation and Cytokine Storm in the ICU and Cardiac Surgery using CytoSorb® Blood Purification
Patented Blood Purification Technology

The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood.

- Proprietary patented technology with 16 issued U.S. patents and multiple patents issued and pending worldwide
- Manufactured at our ISO 13485 certified facility in New Jersey
## Products and Product Pipeline

Internal development supplemented by strong government support with ~$38M in grants, contracts, other non-dilutive funds awarded to our technology from DARPA, NIH, NHLBI, US Army, US Air Force, HHS, and others, to date.

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HemoDefend RBC</strong></td>
<td>Purification of pRBCs</td>
</tr>
<tr>
<td><strong>HemoDefend BGA</strong></td>
<td>Universal Plasma</td>
</tr>
<tr>
<td><strong>CytoSorb-XL</strong></td>
<td>Successor to CytoSorb</td>
</tr>
<tr>
<td><strong>K+ontrol</strong></td>
<td>Severe Hyperkalemia</td>
</tr>
<tr>
<td><strong>ContrastSorb</strong></td>
<td>CT Imaging and Interventional Radiology</td>
</tr>
<tr>
<td><strong>DrugSorb</strong></td>
<td>Drug Overdose</td>
</tr>
</tbody>
</table>

**Marketed**

- Sepsis, Critical Care, High Risk Surgery
- Ex Vivo Organ Perfusion For Transplant
- Critical Illnesses in Animals

**Under Development**

- ECOS-300CY®
- VETRESQ®
CytoSorb is “Plug and Play” High Margin Razorblade

Compatible with Existing Blood Pump Infrastructure In Hospitals Today

**Dialysis or CRRT**
(Continuous Renal Replacement Therapy)

**ECMO**
(Extracorporeal Membrane Oxygenation)

**Hemoperfusion**
(Standalone Treatment)

**CPB**
(Cardiopulmonary Bypass)
CytoSorbents At a Glance (NASDAQ: CTSO)

• CytoSorbents is a rapidly growing NJ-based NASDAQ-traded medical device company

• CytoSorb® is E.U. approved and commercialized in 67 countries as an extracorporeal cytokine adsorber to help treat deadly inflammation where cytokines are elevated (e.g. “cytokine storm”).

• Overall, we have shipped more than 121,000 devices to date. Also, treated >5,000 COVID-19 patients in 30+ countries, including in the U.S. under FDA Emergency Use Authorization for use in critically-ill, adult COVID-19+ patients with respiratory failure

• CytoSorb is also E.U. approved to remove bilirubin (liver dialysis), myoglobin (trauma), and blood thinners Brilinta® (ticagrelor) and Xarelto® (rivaroxaban) during cardiothoracic surgery

• CytoSorb is on a dual path to potential U.S. FDA approval
  • FDA Breakthrough Designation to remove Brilinta (ticagrelor) during emergent and urgent cardiothoracic surgery – targeting a $250M total addressable market in the U.S.
  • U.S. REFRESH 2-AKI Trial – 400 patient pivotal study using CytoSorb intraoperatively to reduce post-op AKI

• Partnered with leading companies:

* CytoSorb has been authorized by the FDA under an EUA for use in COVID-19 patients and will remain active until terminated by the Agency. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection.
Pre-Announcement of Q4 2020 and Full Year 2020 Preliminary Unaudited Financials

CytoSorbents sells through a hybrid sales model, with ~65% of sales from direct sales in 10 countries in Europe, including Germany, and the rest from distributors/partners in 57 other countries

- Cumulative CytoSorb treatments delivered surpassed 121,000, from 80,000 at end of 2019
- 2020 Total Revenue (product sales and grant income) was ~40.8M versus $24.9M in 2019
- 2020 Total Product Sales accelerated to ~$39.5M versus $22.8M in 2019, a 73% increase
- Q4 2019 Product Sales growth increased to ~$11.5M, a 74% increase vs $6.6M in 2019
- Preliminary blended product gross margins are expected to approach 80% for Q4 2020
- Cash balance at 2020 year end was in excess of $71M, with no long term debt
Quarterly Product Sales

Q4 2020 product sales were a record high of ~$11.5M
Continued Annual Sales Growth and Blended Product Margin Expansion

Q4 2020 Estimated Gross Margin of ~80%
What is the U.S. Opportunity?
EU Approval to Remove Ticagrelor and Rivaroxaban “Blood Thinners” During Cardiothoracic Surgery

CytoSorb has received E.U. approval to remove two well-known blockbuster “blood thinners” during cardiothoracic surgery, used in millions of patients to reduce risk of stroke and heart attacks.

**Problem:** Patients that require emergent or urgent cardiothoracic surgery on these blood thinners can develop serious bleeding complications.

- **Ticagrelor (Brilinta®, Brilique® - Astra-Zeneca)** is a blockbuster P2Y$_{12}$ anti-platelet agent (“blood thinner”) with more than $1.6$ billion in worldwide sales, used in patients with acute coronary syndrome.

- **Rivaroxaban (Xarelto® – Bayer, Janssen/J&J)** is a blockbuster Factor Xa inhibitor anti-coagulant (“blood thinner”) with ~$7$ billion in 2019 global sales used as lifelong therapy in patients with atrial fibrillation.

CytoSorb installs easily into a heart-lung machine or cardiopulmonary bypass machine and as blood flows through the cartridge, removes these drugs rapidly during surgery and >90% from whole blood in CPB simulations to reverse their anti-coagulant effect.

We believe CytoSorb can quickly become a cost-effective standard of care to prevent bleeding due to anti-thrombotics, helping to drive sales growth.
Risk of Bleeding Is High in CABG Patients on Ticagrelor

In the ticagrelor registration PLATO ( PLAeleT inhibition and patient Outcomes) trial, 1584 patients underwent CABG surgery, randomized between those who received either ticagrelor or clopidogrel. Those patients (%) with life-threatening bleeding are shown. Bleeding risk is high despite waiting up to 7 days off the drug prior to surgery.

Figure 2 – ‘Major fatal/life-threatening’ CABG-related bleeding by days from last dose of study drug to CABG procedure (PLATO)

<table>
<thead>
<tr>
<th>Days</th>
<th>Ticagrelor (T)</th>
<th>Clopidogrel (C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>55/84</td>
<td>52/88</td>
</tr>
<tr>
<td>2</td>
<td>50/106</td>
<td>42/86</td>
</tr>
<tr>
<td>3</td>
<td>56/114</td>
<td>33/73</td>
</tr>
<tr>
<td>4</td>
<td>39/64</td>
<td>29/69</td>
</tr>
<tr>
<td>5</td>
<td>22/79</td>
<td>27/96</td>
</tr>
<tr>
<td>6</td>
<td>29/91</td>
<td>45/110</td>
</tr>
<tr>
<td>7</td>
<td>25/74</td>
<td>40/107</td>
</tr>
<tr>
<td>&gt;=8</td>
<td>53/228</td>
<td>73/274</td>
</tr>
</tbody>
</table>

**PLATO Major bleed, fatal/life-threatening:** any major bleed as described above and associated with a decrease in Hb of more than 5 g/dL (or a fall in hematocrit (Hct) of at least 15%); transfusion of 4 or more units.

**Fatal:** A bleeding event that directly led to death within 7 days.

* Astra Zeneca Prescribing Information for Ticagrelor
By Removing Drug, CytoSorb Reduces Bleeding Complications

<table>
<thead>
<tr>
<th></th>
<th>43 patients emergency surgery with ticagrelor</th>
<th>55 patients</th>
<th>12 patients emergency surgery with rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPB + CytoSorb</td>
<td>32 patients with intra-operative CytoSorb</td>
<td>11 patients</td>
<td>CPB + CytoSorb</td>
</tr>
<tr>
<td></td>
<td>(n=32)</td>
<td>control</td>
<td>(n=7)</td>
</tr>
<tr>
<td></td>
<td>CPB alone</td>
<td>without</td>
<td>CPB alone</td>
</tr>
<tr>
<td></td>
<td>(n=11)</td>
<td>CytoSorb</td>
<td>(n=5)</td>
</tr>
<tr>
<td>Procedure duration** (min; mean ± SD)</td>
<td>288 ± 63</td>
<td>353 ± 84</td>
<td>184 ± 97</td>
</tr>
<tr>
<td>Red blood cell transfusion</td>
<td>21.9% (n=7)</td>
<td>45.5% (n=5)</td>
<td>14.3% (n=1)</td>
</tr>
<tr>
<td>Platelet transfusion</td>
<td>34.4% (n=11)</td>
<td>100% (n=11)</td>
<td>100% (n=5)</td>
</tr>
<tr>
<td>Chest tube drainage remove volume/24hrs (ml; median [IQR])</td>
<td>350 [300 - 450]</td>
<td>890 [630 - 1025]</td>
<td>390 [310 - 430]</td>
</tr>
<tr>
<td>Re-thoracotomy</td>
<td>0% (n=0)</td>
<td>36.4% (n=4)</td>
<td>0% (n=0)</td>
</tr>
<tr>
<td>Total length of stay (days; median [IQR])</td>
<td>11 [9 - 12]</td>
<td>14 [10 - 16]</td>
<td>11 [10 - 13]</td>
</tr>
</tbody>
</table>

In a separate analysis done in the U.K., this has translated into a projected cost savings to the hospital of approximately $5,000 per patient, including the cost of CytoSorb.
United States TAM for Ticagrelor Removal

50,000 patients on ticagrelor needing emergent/urgent open heart surgery annually in US

$5,000 per device

$250 M Initial U.S. Total Addressable Market

Ticagrelor market share expected to grow
  • CytoSorb makes ticagrelor the only reversible platelet inhibitor
  • Ticagrelor goes off patent in 2024 leading to drop in prices

$500 M U.S. Total Addressable Market

FDA Breakthrough Designation Sets Stage for Potential Expedited U.S. Regulatory Path

- In April 2020, the FDA granted Breakthrough Designation to CytoSorb to remove ticagrelor during cardiopulmonary bypass in emergent or urgent cardiothoracic surgery – a “fast track” for a major unmet medical need

- We will have more clarity soon on U.S. regulatory path forward that is consistent with Breakthrough Designation status

- Recently hired David Cox as Vice President of Global Regulatory Affairs to help drive approval
  - Former Vice President of Regulatory Affairs for Tissue and Regenerative Technologies at Integra LifeSciences

- Also, recently hired James Komsa as Vice President of US Sales and Marketing to initially manage U.S. COVID-19 sales, but to begin commercialization strategy and build-out ahead of potential U.S. ticagrelor approval.
  - Former Vice President at Medtronic of the Restorative Therapy Group (RTG) and Pain, and former VP of Northeast Region, Cardiac and Vascular Group (CVG)

- New CMS approval of Medicare Coverage of Innovative Technology establishes automatic national Medicare coverage for Breakthrough Devices for 4 years
Addressable U.S. Market For Current and Potential Future Indications for Antithrombotic Removal by CytoSorb

- **TICAGRELOR + NOAC**
  - All surgery: $1.5B
  - Cardiac surgery: $500M
  - Cardiac surgery (Additional future): $250M
  - Cardiac surgery (Today): $250M
CytoSorbents has the potential to become a highly profitable elite performer in the therapeutics space with industry leading operating profit margins

- High margin razorblade business model with excellent operating leverage and a solid track record of ex-US growth

- Strong foundation and well-funded for potential future growth, with new and existing clinical applications that address major unmet medical needs

- Working to drive U.S. FDA approval by leveraging FDA Breakthrough Designation of CytoSorb for ticagrelor (Brilinta®) removal. Believe CytoSorb can rapidly become standard of care and capture an initial $250M opportunity

- We have extensive validation from physicians around the world, leading strategic partners, U.S. government agencies, and the media

- Additional near-term catalysts could include new clinical data, clarity on U.S. regulatory path under Breakthrough Designation, sales progress, and many others